Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Overview of attention for article published in Journal of Hematology & Oncology, October 2013

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 90 Dimensions

Readers on

mendeley: 68 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,940 followers.

@dougheuringaria @avidresearch 24 week spleen response for ruxolitinib treatment of those w/ platelet <10^5/uL: 27% http://t.co/Dxz39mgwdi

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.